Thelansis

  HSCT TMA syndrome is clinically represented by microangiopathic hemolytic anemia, renal dysfunction, and neurological symptoms. Its occurrence after transplant depends on a variety of factors, including HLA mismatch, conditioning, and immunosuppressive regimens, presence of GVHD, and infectious complications. Characteristic histopathological findings include thickened capillary walls, occluded vascular lumens by microthrombi and endothelial separation with swelling and necrosis. The incidence of HSCT-TMA ranges from 0.5% to 76%, with a mortality rate of 60-90% despite treatment. The competitive landscape of HSCT–Associated Thrombotic Microangiopathy includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary. KOLs insights of HSCT–Associated Thrombotic Microangiopathy across 8 MM market from the centre of Excellence/ Public/ Private h...